IRVINE, Calif., Oct. 3, 2014 /PRNewswire/ -- Edwards Lifesciences
Corporation (NYSE: EW), the global leader in the science of heart
valves and hemodynamic monitoring, today announced that
David E.I. Pyott, a member of the
company's Board of Directors, has submitted his resignation,
effective today, in order to devote more time to his role as
chairman and chief executive officer of Allergan, Inc.
"The board and I are truly appreciative of David's service and
commitment to Edwards during the last 14 years," said Michael A. Mussallem, Edwards' chairman and
CEO. "David's extensive global experience in leadership roles
at innovative health and nutrition companies made him a valuable
resource for our company. He has been a trusted partner and
brought important expertise to Edwards in delivering novel
therapies to address the needs of patients. We wish him the
best and thank him for the significant role he has played in
Edwards' growth and success."
Pyott joined Edwards' board of directors in 2000, when Edwards
was established as an independent, publicly-held corporation.
About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of
heart valves and hemodynamic monitoring. Driven by a passion
to help patients, the company partners with clinicians to develop
innovative technologies in the areas of structural heart disease
and critical care monitoring, enabling them to save and enhance
lives. Additional company information can be found at
edwards.com.
Edwards, Edwards Lifesciences and the stylized E logo are
trademarks of Edwards Lifesciences Corporation.
Logo - http://photos.prnewswire.com/prnh/20140714/126903
SOURCE Edwards Lifesciences Corporation